Skip to main content
Aprogen, Inc logo

Aprogen, Inc — Investor Relations & Filings

Ticker · 007460 ISIN · KR7007460009 KO Manufacturing
Open in API
Filings indexed 718 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country KR South Korea
Listing KO 007460

About Aprogen, Inc

https://www.aprogen.com/en/v.do?a=Main

Aprogen, Inc. is a biopharmaceutical company focused on the research, development, and manufacturing of biologic medicines. The company's core activities are centered on developing both biosimilars and novel drugs, including new protein therapeutics and bispecific antibodies. Its product development is based on proprietary technologies in antibody engineering and recombinant protein engineering.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Regulatory Filings
2026-04-30 Korean
[기재정정]주요사항보고서(유상증자결정)(자회사의 주요경영사항) (제3자배정)
Share Issue/Capital Change Classification · 1% confidence The document is a Korean Material Event Report (“주요사항보고서”) correcting details of a paid-in capital increase via a third-party allocation (new share issuance). It provides exhaustive details on the number of shares, issue price, allocation, schedule, and related capital change specifics. This corresponds to our 'Share Issue/Capital Change' category rather than a general earnings or management report. Therefore, the correct classification is SHA.
2026-04-29 Korean
주요사항보고서(유상증자결정)(자회사의 주요경영사항) (제3자배정)
Share Issue/Capital Change Classification · 1% confidence The document is a formal ‘주요사항보고서’ filed with the Financial Services Commission and Korea Exchange detailing a paid‐in capital increase (‘유상증자 결정’), specifying new share counts, issue price, discount rate, allotment method (third‐party allotment), subscription and listing dates. This is a direct announcement of a new share issue/capital change rather than an earnings release, proxy statement, or annual report. It therefore fits the Share Issue/Capital Change category (SHA).
2026-04-28 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a Korean major items report filed with the Financial Services Commission and Korea Exchange announcing the decision to issue 30th series private convertible bonds by Aprogen (전환사채권 발행결정). It details bond amounts, interest payment dates, conversion price calculation, adjustment clauses, early redemption options, funds usage, and issuance process. This is a clear announcement of a financing activity (capital raising via convertible bond issuance), fitting the “Capital/Financing Update” category.
2026-04-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a ‘임원ㆍ주요주주 특정증권등 소유상황보고서’ – a mandatory insider holding report filed by officers/major shareholders in Korea. It details share counts, ownership ratios, and acquisition/disposal transactions. This matches the definition for Director’s Dealing (insider trades) filings.
2026-04-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a Korean “주식등의 대량보유상황보고서” (Report on large holdings of shares) filed under the Capital Markets Act to disclose changes in substantial shareholdings, listing the reporting shareholder, related parties, exact numbers and percentages, and reasons for changes. This is a notification of significant share ownership changes crossing disclosure thresholds—not an annual/interim report, earnings release, management change announcement, or proxy statement. It fits the “Major Shareholding Notification” category (Code: MRQ).
2026-04-24 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.